Home > Healthcare > Medical Devices > Diagnostic Devices > Neurological Biomarkers Market

Neurological Biomarkers Market Trends

Report ID: GMI12334
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Neurological Biomarkers Market Trends

The rising prevalence of neurological disorders, coupled with technological advancements is a significant driver of the market.

Advanced biomarkers, including genomic, proteomic, and imaging-based markers, have enhanced the diagnosis and treatment of neurological diseases. These innovations enable faster drug development, earlier detection, and non-invasive testing methods. The growing use of digital biomarkers is also enhancing clinical decision-making in pharmaceutical trials, which is anticipated to drive market growth.
Additionally, the increasing use of biomarkers in precision medicine is transforming the treatment of neurodegenerative diseases, including Alzheimer's, Parkinson's, and multiple sclerosis.
This precision-based approach helps in identifying disease-specific biomarkers, leading to more targeted and effective treatments, which is further propelling market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global neurological biomarkers industry was valued at USD 9.5 billion in 2024 and is estimated to grow at a 10.9% CAGR from 2025 to 2034, driven by the rising prevalence of neurodegenerative diseases.

The proteomic biomarker segment was valued at USD 3.1 billion in 2024, bolstered by innovations in proteomics that enhance the detection and quantification of biomarkers.

The U.S. neurological biomarkers market was valued at USD 3.7 billion in 2024, driven by the increasing prevalence of disorders such as Alzheimer's and Parkinson's.

Key players in the industry include Abbott Laboratories, ACOBIOM, Alseres Pharmaceuticals, Banyan Biomarkers, Bio-Rad Laboratories, DiaGenic ASA, Johnson & Johnson Services, Merck KGaA, QIAGEN, and Quanterix.